Evelyn Wong· @EvelynWongYT · X·· 19 hours agoScore45
Body
Thoughtful discussion by Lisa Salvatore: Temab-A + Bev shows promise in mCRC, but haematological toxicity matters.
Questions unanswered: What does Bev add? Can c-Met guide selection? What is the optimal dose? Awaiting Phase III validation #ESMO26 #ESMOAmbassadors @OncoAlert
23 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1017Pmatched by Developmental therapeutics
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663matched by - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.orgSource: Evelyn Wong · x.com